Therapeutic drug monitoring of digoxin–20 years of experience

Autor: Grzegorz Grześk, Wioleta Stolarek, Marek Krzyżanowski, Katarzyna Szadujkis-Szadurska, Michał Kasprzak, Michał Wiciński, Elżbieta Grześk
Rok vydání: 2018
Předmět:
Male
Drug
Digoxin
medicine.medical_specialty
Cardiotonic Agents
Time Factors
media_common.quotation_subject
Administration
Oral
030204 cardiovascular system & hematology
Gastroenterology
Drug Administration Schedule
03 medical and health sciences
Sex Factors
0302 clinical medicine
Pharmacotherapy
Therapeutic index
Risk Factors
Internal medicine
polycyclic compounds
medicine
Humans
cardiovascular diseases
Aged
Retrospective Studies
media_common
Heart Failure
Pharmacology
medicine.diagnostic_test
business.industry
digestive
oral
and skin physiology
Arrhythmias
Cardiac
Atrial fibrillation
General Medicine
Middle Aged
medicine.disease
carbohydrates (lipids)
Treatment Outcome
Therapeutic drug monitoring
030220 oncology & carcinogenesis
Heart failure
Anesthesia
Population study
Administration
Intravenous
Female
Poland
Drug Monitoring
business
medicine.drug
Zdroj: Pharmacological Reports. 70:184-189
ISSN: 1734-1140
Popis: Background Digoxin is the oldest drug used in the pharmacotherapy of heart failure (HF). However, digoxin remains an important therapeutic option for patients with persistent symptoms of HF occurring despite the implementation of standard pharmacotherapy. Digoxin concentration serum (SCD) should equal 1–2 ng/ml. The aim of our study was to measure of SCD among the hospitalized patients as well as to determine the selected factors influencing the concentration of the digoxin in the blood. Methods The presented research was based on a retrospective analysis including 2149 patients treated with digoxin and hospitalized between 1980 and 2000. Was used for the determination of SCD automatic analyzer TDX ABBOTT GmbH – fluorescence polarization immunoassay (FPIA), with therapeutic range for digoxin of 0.8–2.0 ng/ml. Results Average SCD result in the study population was located within the therapeutic range and amounted 1.06 ng/ml (55.7% of patients). Statistically significant differences in digoxin level were observed depending on the way of medicine administration ( p = 0.000001) and the daily amount ( p = 0.001). Moreover, statistically significant differences in digoxin level were observed depending on sex ( p = 0.00002). Conclusions An elevated level of digoxin was observed in the case of patients who received the medication both orally and intravenously, together with an increase in the daily amount of digoxin doses. It was confirmed that an elevated digoxin level occurs in the course of treatment in the case of women.
Databáze: OpenAIRE
Externí odkaz: